钇90微球管理专家共识

Experts consensus on management of yttrium-90 microspheres

我国肝癌患病人数居于世界首位,严重威胁人民生命健康。钇90微球在国外已应用近20年,对原发性肝癌以及转移性肝癌疗效确切、不良反应少。值此钇90即将于国内上市之际,为指导相关临床医护人员更规范地使用钇90微球,国内从事恶性肿瘤治疗的介入放射学专家就钇90微球治疗肝恶性肿瘤的相关管理办法进行充分深入讨论后达成本共识。

The amount of patients suffering from hepatocellular carcinoma(HCC)in China ranks the first in the world,posing a serious threat to the health and fitness.Yttrium 90 microspheres have been used abroad for nearly 20 years,which have definite curative effect in primary liver cancer and metastatic liver cancer with few side effects.On the occasion of yttrium 90 going to be launched in China,in order to guide relevant clinical staff to use yttrium 90 microspheres in a more standardized manner,domestic interventional radiologists engaged in treatment of malignant tumors conducted a discussion on the hospital management of yttrium 90 microspheres for treatment of liver malignant tumors and reached this experts consensus.